Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
Phase 1 Completed
3 enrolled 12 charts
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
Phase 1 Completed
20 enrolled 9 charts
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Phase 1 Completed
21 enrolled 15 charts
Breast49
Phase 1 Completed
13 enrolled
Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
Phase 1 Completed
15 enrolled
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Phase 1 Completed
30 enrolled
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Phase 1 Completed
30 enrolled
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
Phase 1 Completed
61 enrolled
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Phase 1 Completed
63 enrolled
Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only
Phase 1 Completed
37 enrolled
Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer
Phase 1 Completed
19 enrolled
Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia
Phase 1 Completed
27 enrolled
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled
MS-275 in Treating Patients With Hematologic Cancer
Phase 1 Completed